Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere are no tirzepatide capsules licensed in the UK. Tirzepatide comes as a once-weekly subcutaneous injection, sold under the brand name Mounjaro. If you've been searching for a tablet or capsule form of tirzepatide, you're not alone — but right now, that form simply doesn't exist in the UK market. Tirzepatide is a prescription-only medicine, and any decision about starting it rests with a qualified prescriber who has reviewed your health in full.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks goes something like this: "Is there a tablet version of Mounjaro I can take instead of injecting?" It's a completely understandable thing to wonder. Oral medicines feel familiar. The idea of a weekly injection can put people off before they've even looked into it properly.
The short answer is: tirzepatide capsules do not exist as a licensed UK product. The confusion likely has two sources. First, there is now an oral GLP-1 weight-loss medicine available in the UK, but it's not tirzepatide; it's oral semaglutide (Wegovy tablets), which the MHRA approved in June 2026. Second, some people encounter US-based news or social media posts about pipeline research into oral tirzepatide, and it reaches the UK internet without the crucial context that none of it has been licensed here. If you've seen a seller offering tirzepatide in capsule or tablet form, that is a serious red flag. Tirzepatide is a prescription-only medicine; legitimate supply in the UK comes through the licensed injection pen, via a pharmacy you can verify on the GPhC register.
Understanding what tirzepatide actually is helps explain why it currently has to be injected. The molecule works at two gut-hormone receptors simultaneously (GIP and GLP-1) suppressing appetite and slowing gastric emptying. Large proteins like this are broken down by stomach acid before they can be absorbed orally without a specialist co-formulation. Developing that co-formulation takes years of pharmaceutical work and separate regulatory review. The injection pen sidesteps all of that.
If you want a fuller picture of the treatment before reading on, our Mounjaro page covers the medicine in detail, from how it works to what the prescribing process looks like. Mounjaro comes as a pre-filled KwikPen in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Treatment starts at 2.5 mg. That first pen is about settling your system into the medicine, not producing therapeutic weight loss straight away, and your prescriber manages any step-ups from there based on how you're tolerating it.
Each pen delivers four weekly doses, so you're only opening a new one once a month. The injection goes just under the skin (abdomen, thigh or upper arm) and takes seconds. Most people find it far less daunting than they expected. The pen is stored in the fridge, and the patient information leaflet (available via the eMC) gives the precise room-temperature window if you're travelling.
The clinical evidence behind the injection is substantial. SURMOUNT-1, a 72-week trial involving 2,539 adults, reported average body-weight reductions of around 20–21% at 15 mg alongside lifestyle changes. A head-to-head trial published in 2025 found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. These are the figures that supported NICE's recommendation of tirzepatide for weight management in December 2024. You can read the full NICE TA1026 appraisal for the eligibility criteria in detail.
If you arrived at "tirzepatide capsules" partly because you're weighing up options for weight management, it's worth knowing who Mounjaro is actually licensed for in the UK. The licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition, such as high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't guarantee a prescription; a prescriber looks at the whole clinical picture, including any medicines you're already taking and relevant medical history.
For context on what private treatment involves financially, the treatment page sets out what's included in a private consultation route. Tirzepatide is a prescription-only medicine, so the price always has to include clinical assessment, any listing that doesn't is not a legitimate supply route.
Common side effects are mostly gastrointestinal: nausea, loose stools or constipation, burping and indigestion are the ones people mention most, and they tend to be most noticeable in the first week or two after starting or after a dose increase. Serious reactions are uncommon but exist; severe, persistent abdominal pain that radiates to the back needs prompt medical attention. The NHS tirzepatide page covers side effects and when to seek help clearly.
Preference for an oral medicine is completely valid and worth exploring. The oral GLP-1 option now licensed in the UK is Wegovy tablets (oral semaglutide), approved by the MHRA in June 2026. It uses a different mechanism to tirzepatide, is taken daily rather than weekly, and trial data showed average weight loss of around 13.6% over 64 weeks. It's a different medicine, and whether it suits you depends on your health profile, that's a conversation for a prescriber.
If the idea of injecting is the main barrier, it's genuinely worth talking to a clinical team before ruling tirzepatide out. The pen design is straightforward, and many people are surprised by how manageable it is once they've seen one. Our clinical team at nume includes GPhC-registered Independent Prescribers who can answer exactly this kind of question. You can also read a broader overview of tirzepatide as a treatment before going any further, and if you're trying to decide whether Mounjaro or tirzepatide is the right way to think about your options, that page unpacks the relationship between the two.
A prescriber's review is the right starting point, not because it's a formality, but because getting the medicine right for your situation actually matters. Those questions often include things like which tirzepatide l strength might be appropriate over time, or whether the tirzepatide 30-day supply format suits your routine, and a prescriber can work through all of that with you. Check your eligibility and start a free consultation at weight-loss-treatments.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.